01423 887951
info@townsendinvestments.com
info@townsendinvestments.com
Congratulations to Peter Townsend and Georgina Townsend who on the 24th September 2016 represented Townsend I...
Read More
Dr Deborah O'Neil will present data on Novamycin, a novel peptide antifungal intervention for clinically challenging mycoses in immunocompromised patients.
The 2016 Boul...
Read More
Reset is proud to welcome two new NHS Trusts to the Reset Certification Scheme.
Hinchingbrooke Health Care NHS Trust and Queen Elizabeth Hospital Kings Lynn NHS Trust have joined the Res...
Read More
NovaBiotics Ltd, the UK-based clinical-sta...
Read More
ENGIE in the UK has chosen Reset Certification Scheme (Reset) to help manage, monitor and control the competence of contractors.
In an assertive move to lead the way, the company-...
Read More
NOVABIOTICS "ONE TO WATCH" FOR 2017.
NovaBiotics has been shortlisted for Biotech & Money's 2016 Assembly & Awards Gala Dinner (to be held ...
Read More
NovaBiotics Ltd (‘NovaBiotics’ or the ‘Company’), the Aberdeen-based clinical-stage biotechnology company, has presented new data showing antibiotic resi...
Read More
NovaBiotics announces today that Principal Scientist, Dr Douglas Fraser-Pitt will be presenting new data on antibiotic resistance at ASM Microbe 2016, Boston, USA, 16-20 June.
Dr Fra...
Read More
NovaBiotics announces today that three sets of new data will be presented at this year’s European Cystic Fibrosis (CF) Society Conference, taking place in Basel, Switzerla...
Read More
New multi-action, multi-strain anti-infectives needed to win battle against AMR
CEO Dr Deborah O’Neil today stated that a multi-attack and multi-strain approach to the ...
Read More
CEO Dr Deborah O’Neil will be presenting in a workshop at this year’s BIO International’s ‘Focus on Anti-Infectives: Innovation for AMR’ in San Francisco, taking place...
Read More
COMBATTING ANTIMICROBIAL RESISTANCE (AMR) WITH ANTIBIOTIC RESISTANCE BREAKING TECHNOLOGY.
ASM MICROBE 2016.
NovaBiotics has been selected to present exciting new data on antibiotic resi...
Read More
Robert Gordon University's School of Pharmacy & Life Sciences approached NovaBiotics about an award for their best third year student of the Applied Biomedical Science route.
We were de...
Read More
NOVABIOTICS’ POD, PRESENTATIONS AND PARTNERING PLANS!
Deborah O’Neil, NovaBiotics CEO and CSO is looking forward to a very busy and productive BIO Read More
LYNOVEX CLINICAL TRIAL DATA PUBLISHED
PhIIa CLINICAL TRIAL DATA FOR LYNOVEX (CYSTEAMINE) IN CYSTIC FIBROSIS PUBLISHED IN CLINICAL DRUG INVESTIGATION.
As part of Lynovex’s continue...
Read More
NOVABIOTICS TO PRESENT EXCITING NEW DATA AT ECFS 2016
PRESENTATIONS ON THE APPLICATION OF LYNOVEX AND NOVAMYCIN IN CYSTIC FIBROSIS
NovaBiotics scientific team will be in force and very ...
Read More
NOVABIOTICS ANNOUNCES THE ACCEPTANCE OF THREE ABSTRACTS FOR PRESENTATION AT ECFS 2016.
Three of NovaBiotics' recent studies from within the company's cystic fibrosis (CF) p...
Read More
NovaBiotics and the University of Strathclyde secure Knowledge Transfer Partnership grant funding.
NovaBiotics are pleased to announce successful...
Read More
Aberdeen, UK – 5th February 2016 – NovaBiotics Ltd, the Aberdeen-based, anti-infectives focused biotechnology company (“NovaBiotics” or the “Company”), today ann...
Read More